What is BioBDx?
BioBehavioral Diagnostics Company, known as BioBDx, operates at the intersection of neurology and medical technology. The firm specializes in the development, manufacturing, and commercialization of proprietary diagnostic systems designed to provide quantitative data for behavioral health assessments. Its flagship innovation, the McLean Motion and Attention Test (MMAT/ADHD System), serves as a critical tool for clinicians, enabling objective, office-based diagnoses for Attention Deficit Hyperactivity Disorder. By replacing subjective evaluation methods with data-driven metrics, BioBDx ensures that patients receive prompt and appropriate therapeutic interventions, thereby improving long-term clinical outcomes in the behavioral health sector.
How much funding has BioBDx raised?
BioBDx has raised a total of $22.3M across 4 funding rounds:
Series A
$8.5M
Series B
$10M
Debt
$700K
Debt
$3.1M
Series A (2007): $8.5M with participation from Sevin Rosen Funds' companies and Tullis-Dickerson & Co.
Series B (2010): $10M led by Sevin Rosen Funds and Tullis Health Investors
Debt (2011): $700K, investors not publicly disclosed
Debt (2011): $3.1M, investors not publicly disclosed
Key Investors in BioBDx
Sevin Rosen Funds
A Texas-based venture capital firm with a legacy of pioneering the personal computing revolution and supporting high-growth technology ventures since 1981.
Tullis Health Investors
A private equity firm specializing in commercial-stage healthcare companies, focusing on medical devices, biotechnology, and scalable healthcare services.
Tullis-Dickerson & Co.
An investment firm focused on providing strategic capital to healthcare enterprises, often operating in tandem with specialized health-focused funds.
What's next for BioBDx?
With the recent capital injection, BioBDx is positioned to accelerate the market penetration of its MMAT/ADHD System. The strategic focus will likely shift toward expanding clinical adoption and refining the diagnostic platform to accommodate broader behavioral health applications. As the company moves beyond its initial scaling phase, the emphasis will remain on maintaining high-fidelity diagnostic standards while navigating the regulatory landscape of medical devices. Future growth will be predicated on the firm's ability to integrate its technology into standard clinical workflows, ultimately establishing a new benchmark for objective behavioral health diagnostics in both domestic and international markets.
See full BioBDx company page
